Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

RNAZ

TransCode Therapeutics (RNAZ)

TransCode Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:RNAZ
DateTimeSourceHeadlineSymbolCompany
04/15/20248:00AMGlobeNewswire Inc.TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid TumorsNASDAQ:RNAZTransCode Therapeutics Inc
04/03/20248:10AMGlobeNewswire Inc.TransCode Therapeutics Reports 2023 Results; Provides Business UpdateNASDAQ:RNAZTransCode Therapeutics Inc
03/28/20247:30AMGlobeNewswire Inc.TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical OfficerNASDAQ:RNAZTransCode Therapeutics Inc
03/11/20248:00AMGlobeNewswire Inc.TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer TreatmentNASDAQ:RNAZTransCode Therapeutics Inc
03/06/20243:15PMGlobeNewswire Inc.TransCode Therapeutics To Present At 2024 RNA Leaders Europe CongressNASDAQ:RNAZTransCode Therapeutics Inc
02/20/20247:00AMGlobeNewswire Inc.TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist ImmunotherapeuticNASDAQ:RNAZTransCode Therapeutics Inc
02/15/20243:00PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RNAZTransCode Therapeutics Inc
02/13/20247:12PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RNAZTransCode Therapeutics Inc
01/31/20243:33PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
01/31/20243:05PMGlobeNewswire Inc.Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock MarketNASDAQ:RNAZTransCode Therapeutics Inc
01/29/20247:30AMGlobeNewswire Inc.TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for CancerNASDAQ:RNAZTransCode Therapeutics Inc
01/22/20243:45PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
01/22/20243:45PMGlobeNewswire Inc.TransCode Therapeutics Announces Closing of $7.25 Million Public OfferingNASDAQ:RNAZTransCode Therapeutics Inc
01/19/20248:57PMEdgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:RNAZTransCode Therapeutics Inc
01/18/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:RNAZTransCode Therapeutics Inc
01/18/202412:27PMGlobeNewswire Inc.TransCode Therapeutics Announces Pricing of $7.25 Million Public OfferingNASDAQ:RNAZTransCode Therapeutics Inc
01/18/20249:39AMEdgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:RNAZTransCode Therapeutics Inc
01/17/20246:06AMEdgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:RNAZTransCode Therapeutics Inc
01/16/20243:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
01/12/20243:05PMGlobeNewswire Inc.TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEONASDAQ:RNAZTransCode Therapeutics Inc
01/11/20247:22AMEdgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:RNAZTransCode Therapeutics Inc
01/11/20247:00AMGlobeNewswire Inc.TransCode Therapeutics Announces 1-for-40 Reverse Stock SplitNASDAQ:RNAZTransCode Therapeutics Inc
01/08/20243:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
01/04/202411:41AMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RNAZTransCode Therapeutics Inc
01/04/20247:05AMGlobeNewswire Inc.TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and ObjectivesNASDAQ:RNAZTransCode Therapeutics Inc
12/18/20233:28PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:RNAZTransCode Therapeutics Inc
12/12/20237:30AMGlobeNewswire Inc.TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138NASDAQ:RNAZTransCode Therapeutics Inc
12/08/20233:57PMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:RNAZTransCode Therapeutics Inc
12/08/20233:56PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
12/07/20233:30PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:RNAZTransCode Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:RNAZ